Week In Review: Three China In-Licensing Deals Add Up To $662 Million

Company News 

  • Hangzhou's Ascletis Pharma (HK: 1672) announced that it will expand its focus into oncology (see story). The company was founded to bring effective hepatitis C treatments to China at an affordable price. It has accomplished that, and it now plans to combine its two in-licensed FASN inhibitors with two self-discovered anti-cancer drugs, an EGFR anti-angiogenesis candidate (bevacizumab) and a small molecule PD-1 inhibitor. Initially, it will test a combination of ASC40 and bevacizumab in patients with astrocytoma, a cancer of the brain or spinal cord. 
1 2 3 4
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.